Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. Vitt discussed the progress of Immunic’s lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. In addition, Dr Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which h ...